Heterologous prime-boost with mRNA-1273 stimulates persistent neutralising antibodies in BBIBP-CorV-vaccinated individuals

Vaccine, Journal Year: 2023, Volume and Issue: 41(47), P. 6910 - 6913

Published: Oct. 24, 2023

BBIBP-CorV inactivated vaccine is one of the most prevalent vaccines globally, but immune responses are far less studied than novel COVID-19 platforms. Longitudinal studies on with homologous and heterologous booster doses limited. This study follows a subset participants from national comparing immunogenicity levels SARS-CoV-2 neutralising antibody (NAb). Homologous dose significantly increased NAb in BBIBP-CorV-vaccinated individuals. Similar were observed 1 month following BNT162b2 or mRNA-1273 booster. Interestingly, persisted (n = 95), waned at 6 9 months 50; P > 0.001). The persistence was also breakthrough infection. provides evidence that not all mRNA equal longer term should provide valuable information for policy makers planning programmes vaccinated populations.

Language: Английский

Evaluating long-term antibody responses to booster doses of COVID-19 vaccines in the Pakistani population

Pakistan Journal of Medical Sciences, Journal Year: 2023, Volume and Issue: 40(2(ICON))

Published: Dec. 5, 2023

Background & Objective: Nearly 80 million of the Pakistani population received two doses BBIBP-CorV vaccine, against SARS-CoV-2, and 2.6 people heterologous booster up to February 2022. Our objective was evaluate increase antibody titers in persons vaccinated with Pfizer–BioNTech COVID-19 following BBIBP-CorV. Methods: Serum specimens from forty-three participants were collected 4-8 weeks at Indus Hospital Health Network, Karachi. A second set serum 2-12 months after dose administration. Chemiluminescent Microparticle Immunoassay (CMIA, Abbott Alinity Quant), pseudotyped lentivirus neutralization assay performed on all specimens. The latter reported as log half-maximal inhibitory concentrations (IC50), calculated using a nonlinear regression algorithm (log [inhibitor] versus normalized response variable slope) Graph Pad Prism 9. paired sample t-test used ascertain statistical significance difference means obtained before vaccine doses. Results: Mean log10 values CMIA 2.90 AU/mL 3.87 respectively, while corresponding IC50 through 2.45 2.80. These differences statistically significant (p = <0.00001), but not 0.06318.). Conclusion: BBIBP results increased total titers, though neutralizing may start wane few dose. doi: https://doi.org/10.12669/pjms.40.2(ICON).8951 How cite this: Hussain S, Naseer F, Kanani Aijaz J. Evaluating long-term responses vaccines population. Pak J Med Sci. 2024;40(2):S28-S34. This is an Open Access article distributed under terms Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, reproduction any medium, provided original work properly cited.

Language: Английский

Evaluation of the Diagnostic Performance of Two Automated SARS-CoV-2 Neutralization Immunoassays following Two Doses of mRNA, Adenoviral Vector, and Inactivated Whole-Virus Vaccinations in COVID-19 Naïve Subjects

Microorganisms, Journal Year: 2023, Volume and Issue: 11(5), P. 1187 - 1187

Published: April 30, 2023

Background: Limited data are available on humoral responses determined by automated neutralization tests following the administration of three different types COVID-19 vaccinations. Thus, we here evaluated anti-SARS-CoV-2 neutralizing antibody titers via two assays in comparison to total spike levels. Methods: Healthy participants (n = 150) were enrolled into subgroups who tested 41 (22–65) days after their second dose mRNA (BNT162b2/mRNA-1273), adenoviral vector (ChAdOx1/Gam-COVID-Vac) and inactivated whole-virus (BBIBP-CorV) vaccines, with no history or serologic evidence prior SARS-CoV-2 infection. Neutralizing (N-Ab) analyzed a Snibe Maglumi® 800 instrument Medcaptain Immu F6® Analyzer parallel S (S-Ab) levels (Roche Elecsys® e602). Results: Subjects administered vaccines demonstrated significantly higher N-Ab S-Ab compared those received vaccinations (p < 0.0001). methods correlated each other (r 0.9608; p 0.0001) 0.9432 r 0.9324; 0.0001, respectively). Based values, new optimal threshold Roche was calculated (166 BAU/mL) for discrimination seropositivity showing an AUC value 0.975 Low post-vaccination (median 0.25 μg/mL 7.28 AU/mL) measured 8) infected within 6 months immunizations. Conclusion: Both effective evaluate various

Language: Английский